These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

254 related articles for article (PubMed ID: 36290893)

  • 41. PD-1 Inhibitors in Elderly and Immunocompromised Patients with Advanced or Metastatic Cutaneous Squamous Cell Carcinoma.
    Yakobson A; Abu Jama A; Abu Saleh O; Michlin R; Shalata W
    Cancers (Basel); 2023 Aug; 15(16):. PubMed ID: 37627069
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Neoadjuvant Cemiplimab for Stage II to IV Cutaneous Squamous-Cell Carcinoma.
    Gross ND; Miller DM; Khushalani NI; Divi V; Ruiz ES; Lipson EJ; Meier F; Su YB; Swiecicki PL; Atlas J; Geiger JL; Hauschild A; Choe JH; Hughes BGM; Schadendorf D; Patel VA; Homsi J; Taube JM; Lim AM; Ferrarotto R; Kaufman HL; Seebach F; Lowy I; Yoo SY; Mathias M; Fenech K; Han H; Fury MG; Rischin D
    N Engl J Med; 2022 Oct; 387(17):1557-1568. PubMed ID: 36094839
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population pharmacokinetics modeling and exposure-response analyses of cemiplimab in patients with recurrent or metastatic cervical cancer.
    Nguyen JH; Epling D; Dolphin N; Paccaly A; Conrado D; Davis JD; Al-Huniti N
    CPT Pharmacometrics Syst Pharmacol; 2022 Nov; 11(11):1458-1471. PubMed ID: 36251220
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Diagnostic Delays for Non-melanoma Skin Cancers in Renal Transplant Recipients during the COVID-19 Pandemic: What is Hiding Behind the Mask?
    Mokos M; Bašić-Jukić N
    Acta Dermatovenerol Croat; 2021 Jul; 29(2):111-113. PubMed ID: 34477079
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Case Report: Autoimmune Pemphigus Vulgaris in a Patient Treated With Cemiplimab for Multiple Locally Advanced Cutaneous Squamous Cell Carcinoma.
    Buquicchio R; Mastrandrea V; Strippoli S; Quaresmini D; Guida M; Filotico R
    Front Oncol; 2021; 11():691980. PubMed ID: 34540666
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis.
    Nardone V; Napolitano S; Gagliardi F; Esposito A; Caraglia F; Briatico G; Scharf C; Ronchi A; D'Onofrio I; D'Ippolito E; Russo A; Belfiore MP; Franco R; Argenziano G; Ciardiello F; Reginelli A; Cappabianca S; Troiani T
    J Am Acad Dermatol; 2024 Oct; 91(4):678-683. PubMed ID: 38885840
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Update on the anti-programmed cell death-1 receptor antibodies in advanced cutaneous squamous-cell carcinoma.
    Benzaquen M
    Dermatol Ther; 2020 May; 33(3):e13325. PubMed ID: 32208547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Early discontinuation of cemiplimab in patients with advanced cutaneous squamous cell carcinoma.
    Boutros A; Croce E; Tanda ET; Cecchi F; Arecco L; Genova C; Baldelli I; Lambertini M; Raposio E; Del Mastro L; Spagnolo F
    J Geriatr Oncol; 2024 Mar; 15(2):101640. PubMed ID: 37798175
    [No Abstract]   [Full Text] [Related]  

  • 49. Variable Outcome of Immunotherapy in Advanced Multiple Cutaneous Squamous Cell Carcinomas in Two Patients with Recessive Dystrophic Epidermolysis Bullosa.
    Trefzer L; Hess ME; Scholten L; Technau-Hafsi K; Meiss F; Boerries M; Has C; Rafei-Shamsabadi D
    Acta Derm Venereol; 2023 Jun; 103():adv4870. PubMed ID: 37338146
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Anti-PD1 Agents in the Treatment of Cutaneous Squamous Cell Carcinoma.
    Niu W; Robertson C; Hilton D
    Skinmed; 2022; 20(5):338-342. PubMed ID: 36314696
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Cemiplimab in an Elderly Frail Population of Patients With Locally Advanced or Metastatic Cutaneous Squamous Cell Carcinoma: A Single-Center Real-Life Experience From Italy.
    Strippoli S; Fanizzi A; Quaresmini D; Nardone A; Armenio A; Figliuolo F; Filotico R; Fucci L; Mele F; Traversa M; De Luca F; Montagna ES; Ruggieri E; Ferraiuolo S; Macina F; Tommasi S; Sciacovelli AM; De Risi I; Albano A; Massafra R; Guida M
    Front Oncol; 2021; 11():686308. PubMed ID: 34820323
    [TBL] [Abstract][Full Text] [Related]  

  • 52. First-line programmed death-1 inhibitor treatment for locoregionally advanced or metastatic cutaneous squamous cell carcinoma - A real-world experience from Israel.
    Averbuch I; Salman S; Shtamper N; Doweck I; Popovtzer A; Markel G; Hendler D; Finkel I; Moore A; Fenig E; Taha T; Mhameed K; Kurman N; Billan S
    Front Oncol; 2023; 13():1117804. PubMed ID: 36793605
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Cemiplimab in Ultra-Octogenarian Patients with Cutaneous Squamous Cell Carcinoma: The Real-Life Experience of a Tertiary Referral Center.
    Denaro N; Passoni E; Indini A; Nazzaro G; Beltramini GA; Benzecry V; Colombo G; Cauchi C; Solinas C; Scartozzi M; Marzano AV; Garrone O
    Vaccines (Basel); 2023 Sep; 11(9):. PubMed ID: 37766176
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Cemiplimab for the treatment of advanced cutaneous squamous cell carcinoma.
    Hernández-Guerrero T; Doger B; Moreno V
    Drugs Today (Barc); 2019 Aug; 55(8):485-494. PubMed ID: 31461085
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Update in the treatment of non-melanoma skin cancers: the use of PD-1 inhibitors in basal cell carcinoma and cutaneous squamous-cell carcinoma.
    Ascierto PA; Schadendorf D
    J Immunother Cancer; 2022 Dec; 10(12):. PubMed ID: 36455990
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Cemiplimab for Kidney Transplant Recipients With Advanced Cutaneous Squamous Cell Carcinoma.
    Hanna GJ; Dharanesswaran H; Giobbie-Hurder A; Harran JJ; Liao Z; Pai L; Tchekmedyian V; Ruiz ES; Waldman AH; Schmults CD; Riella LV; Lizotte P; Paweletz CP; Chandraker AK; Murakami N; Silk AW
    J Clin Oncol; 2024 Mar; 42(9):1021-1030. PubMed ID: 38252908
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Immunotherapy in advanced cutaneous squamous cell carcinoma: Sydney west cancer network experience.
    Hasmat S; Howle JR; Carlino MS; Sundaresan P; Veness MJ
    ANZ J Surg; 2023 Jan; 93(1-2):235-241. PubMed ID: 36567642
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Immunotherapy for Non-melanoma Skin Cancer.
    Shalhout SZ; Emerick KS; Kaufman HL; Miller DM
    Curr Oncol Rep; 2021 Aug; 23(11):125. PubMed ID: 34448958
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Real world safety outcomes using cemiplimab for cutaneous squamous cell carcinoma.
    Valentin J; Gérard E; Ferte T; Prey S; Dousset L; Dutriaux C; Beylot-Barry M; Pham-Ledard A
    J Geriatr Oncol; 2021 Sep; 12(7):1110-1113. PubMed ID: 33736973
    [TBL] [Abstract][Full Text] [Related]  

  • 60. European consensus-based interdisciplinary guideline for invasive cutaneous squamous cell carcinoma: Part 2. Treatment-Update 2023.
    Stratigos AJ; Garbe C; Dessinioti C; Lebbe C; van Akkooi A; Bataille V; Bastholt L; Dreno B; Dummer R; Fargnoli MC; Forsea AM; Harwood CA; Hauschild A; Hoeller C; Kandolf-Sekulovic L; Kaufmann R; Kelleners-Smeets NW; Lallas A; Leiter U; Malvehy J; Del Marmol V; Moreno-Ramirez D; Pellacani G; Peris K; Saiag P; Tagliaferri L; Trakatelli M; Ioannides D; Vieira R; Zalaudek I; Arenberger P; Eggermont AMM; Röcken M; Grob JJ; Lorigan P;
    Eur J Cancer; 2023 Nov; 193():113252. PubMed ID: 37708630
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.